34314 Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data

Introduction: Bimekizumab (BKZ) has demonstrated superior clinical responses to adalimumab (ADA), ustekinumab (UST), and secukinumab (SEC) in patients with moderate to severe plaque psoriasis. Number needed to treat (NNT) is a clinically meaningful way to assess comparative effectiveness between treatments, indicating how many patients need to be treated for one additional patient to achieve an outcome vs a comparator.